- RNA therapeutics represent a transformative class of medicines that utilize ribonucleic acid (RNA) to treat or prevent diseases by targeting genetic instructions at the molecular level. These therapies include mRNA, siRNA, miRNA, and antisense oligonucleotides used across a wide range of indications, including cancer, genetic disorders, and infectious diseases
- The market’s growth is significantly driven by the increasing prevalence of chronic and genetic diseases, rising demand for precision medicine, and advancements in RNA delivery technologies. The success of mRNA vaccines during the COVID-19 pandemic has also accelerated interest and investment in RNA-based treatments
- North America leads the global RNA therapeutics market, supported by robust biotechnology infrastructure, favorable regulatory frameworks, and strong investment in R&D from both public and private sectors
- For instance, the U.S. has witnessed substantial funding in RNA biotech startups, and major pharmaceutical players are expanding their RNA therapeutic pipelines through collaborations and acquisitions
- Globally, RNA therapeutics are considered one of the most promising frontiers in biomedicine, ranking alongside gene therapy in their potential to revolutionize the treatment landscape for previously untreatable or hard-to-treat conditions
